StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Non-GAAP effective tax rate by Quarter

Non-GAAP effective tax rate (%) (%)

QuarterlyAnnual

Vertex Pharmaceuticals Non-GAAP effective tax rate: 21.1% in Q2 2026, up 1.7 pts from a year earlier.

Latest, Q2 2026
21.1%
Period ended Jun 30, 2026
Change on a year earlier
+1.7 pts
19.4% in Q2 2025
History
26 quarters
Since Q1 2020
Sources
22
Documents cited below

Where the Q2 2026 figure comes from

“|| Non-GAAP effective tax rate | 21.1 | % | 19.4 | % | 20.4 | % | 19.1 | % 12Vertex Pharmaceuticals Incorporated”

Source: Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗

Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP effective tax rate (%) (%)Year on yearSource
Q2 2026Jun 30, 202621.1%+1.7 ptsForm 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Q1 2026Mar 31, 202619.6%+0.8 ptsForm 8-K (ex-991_q12026.htm, filed 2026-05-04) ↗
Q4 2025Dec 31, 202513.5%-7.8 ptsForm 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Q3 2025Sep 30, 202517.6%-2.2 ptsForm 8-K (ex-991_q32025.htm, filed 2025-11-03) ↗
Q2 2025Jun 30, 202519.4%+29.4 ptsForm 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Q1 2025Mar 31, 202518.8%+1.4 ptsForm 8-K (ex-991_q12026.htm, filed 2026-05-04) ↗
Q4 2024Dec 31, 202421.3%+5.0 ptsForm 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Q3 2024Sep 30, 202419.8%+0.4 ptsForm 8-K (ex-991_q32025.htm, filed 2025-11-03) ↗
Q2 2024Jun 30, 2024-10.0%-31.0 ptsForm 8-K (ex-991_q22025.htm, filed 2025-08-04) ↗
Q1 2024Mar 31, 202417.4%-3.9 ptsForm 8-K (ex-991_q12025.htm, filed 2025-05-05) ↗
Q4 2023Dec 31, 202316.3%-2.2 ptsForm 8-K (ex-991_q42024.htm, filed 2025-02-10) ↗
Q3 2023Sep 30, 202319.4%-2.0 ptsForm 8-K (ex-991_q32024.htm, filed 2024-11-04) ↗
Q2 2023Jun 30, 202321.0%-0.8 ptsForm 8-K (ex-991_q22024.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 202321.3%-0.2 ptsForm 8-K (ex-991_q12024.htm, filed 2024-05-06) ↗
Q4 2022Dec 31, 202218.5%-2.1 ptsForm 8-K (ex-991_q42023.htm, filed 2024-02-05) ↗
Q3 2022Sep 30, 202221.4%+1.4 ptsForm 8-K (ex-991_q32023.htm, filed 2023-11-06) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Non-GAAP effective tax rate (%), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-etr

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.